公开(公告)号：US12091468B2

公开(公告)日：2024-09-17

申请号：US18450194

申请日：2023-08-15

申请人： Omeros Corporation

发明人： Thomas Dudler ,  Peter Kurt Nollert von Specht ,  Munehisa Yabuki ,  Sadam Yaseen

IPC分类号： C07K16/40 ,  A61P3/00

CPC分类号： C07K16/40 ,  A61P3/00 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565

摘要： Isolated monoclonal antibodies and antigen-binding fragments thereof are provided that specifically bind to an epitope within the serine protease domain of human MASP-2. In some embodiments, the antibodies or antigen-binding fragments thereof inhibit lectin pathway complement activation. Also provided are polynucleotides encoding the disclosed monoclonal antibodies or antigen-binding fragments thereof, and cloning vectors or expression cassettes comprising such polynucleotides. Further provided are methods of inhibiting lectin pathway complement activation and methods of treating lectin pathway diseases and disorders.

公开(公告)号：US20240228499A1

公开(公告)日：2024-07-11

申请号：US18523642

申请日：2023-11-29

申请人： Omeros Corporation

发明人： Neil S. Cutshall ,  Jennifer Lynn Gage ,  Do Yeon Kwon ,  Thomas L. Little ,  Markus Metz ,  Peter Kurt Nollert von Specht ,  Jennifer Tsoung ,  Sudheer Babu Vaddela ,  Connor Weidle

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61K31/5377 ,  C07D519/00

CPC分类号： C07D487/04 ,  A61K31/519 ,  A61K31/5377 ,  C07D519/00

摘要： The disclosure provides synthetic compositions useful as inhibitors of mannan-binding lectin-associated serine protease-2 (MASP-2), including compositions that selectively inhibit MASP-2 over thrombin, as well as methods for the manufacture and use thereof.

公开(公告)号：US20240218080A1

公开(公告)日：2024-07-04

申请号：US18411789

申请日：2024-01-12

申请人： Omeros Corporation

发明人： Gregory A. Demopulos ,  Thomas A. Dudler

IPC分类号： C07K16/40 ,  A61P27/10 ,  A61K39/00

CPC分类号： C07K16/40 ,  A61P27/10 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/565 ,  C07K2317/76

摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from, or at risk for developing HSCT-IPS and/or suffering from, or at risk for developing HSCT-CLS and/or suffering from, or at risk for developing HSCT-FO and/or suffering from, or at risk for developing HSCT-ES. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

公开(公告)号：US12005117B2

公开(公告)日：2024-06-11

申请号：US16917157

申请日：2020-06-30

申请人： University of Leicester ,  Omeros Corporation

发明人： Nigel John Brunskill ,  Gregory A. Demopulos ,  Thomas A. Dudler ,  Hans-Wilhelm Schwaeble

IPC分类号： A61P13/12 ,  A61K39/395 ,  C07K16/40 ,  A61K39/00

CPC分类号： A61K39/3955 ,  A61K39/395 ,  A61P13/12 ,  C07K16/40 ,  A61K2039/505 ,  A61K2121/00 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/76 ,  C07K2317/92

摘要： In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

公开(公告)号：US20240092938A1

公开(公告)日：2024-03-21

申请号：US18168192

申请日：2023-02-13

申请人： Omeros Corporation

发明人： Thomas Dudler ,  Wayne R. Gombotz ,  James Brian Parent ,  Clark E. Tedford ,  Anita Kavlie ,  Urs Beat Hagemann ,  Herald Reiersen ,  Sergej Kiprijanov

IPC分类号： C07K16/40 ,  C12N9/64

CPC分类号： C07K16/40 ,  C12N9/6424 ,  C12Y304/21104 ,  A61K2039/505

摘要： The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

公开(公告)号：US11883493B2

公开(公告)日：2024-01-30

申请号：US17241628

申请日：2021-04-27

申请人： Omeros Corporation

发明人： W. Jason Cummings ,  Gregory A. Demopulos ,  Thomas Dudler ,  Larry W. Tjoelker ,  Christi L. Wood ,  Munehisa Yabuki

IPC分类号： A61K39/395 ,  C07K16/40 ,  C01F17/206 ,  B82Y25/00 ,  C09K11/77 ,  H01F1/00 ,  C12N9/64 ,  A61K39/00

CPC分类号： A61K39/3955 ,  B82Y25/00 ,  C01F17/206 ,  C07K16/40 ,  C09K11/77 ,  C09K11/7728 ,  C12N9/6424 ,  C12Y304/21104 ,  H01F1/0054 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C01P2002/54 ,  C01P2002/84 ,  C01P2004/64 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92

摘要： The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.

公开(公告)号：US20230391889A1

公开(公告)日：2023-12-07

申请号：US18152536

申请日：2023-01-10

申请人： University of Leicester ,  Omeros Corporation

发明人： Hans-Wilhelm Schwaeble ,  Cordula Margaret Stover ,  Clark E. Tedford ,  James Brian Parent ,  Teizo Fujita

IPC分类号： C07K16/40 ,  A01K67/027 ,  A61K39/395 ,  A61K49/00 ,  C12N9/64

CPC分类号： C07K16/40 ,  A01K67/0276 ,  A61K39/395 ,  A61K49/0008 ,  C12N9/6408 ,  C12N9/6424 ,  C12Y304/21104 ,  C07K2317/76 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A61K2039/505

摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

公开(公告)号：US11628217B2

公开(公告)日：2023-04-18

申请号：US15691266

申请日：2017-08-30

申请人： Omeros Corporation

发明人： Gregory A. Demopulos ,  Kenneth M. Ferguson ,  William Joseph Lambert ,  John Steven Whitaker

IPC分类号： A61K39/395 ,  C07K16/40 ,  A61K9/08 ,  A61K47/12 ,  A61P25/26 ,  A61K9/00 ,  A61K47/18 ,  A61K47/26

摘要： The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 dependent complement activation.

公开(公告)号：US20230110784A1

公开(公告)日：2023-04-13

申请号：US17823793

申请日：2022-08-31

申请人： Omeros Corporation

发明人： Gregory A. Demopulos ,  George A. Gaitanaris ,  Roberto Ciccocioppo

IPC分类号： A61K31/551 ,  A61K31/5513 ,  A61K31/5377 ,  A61K31/53 ,  A61K31/4985 ,  A61K31/496 ,  A61K31/519 ,  A61K31/527 ,  A61K31/46 ,  A61K31/435 ,  A61K31/4439 ,  A61K31/433 ,  A61K31/4178 ,  A61K31/4162 ,  A61K31/4025 ,  A61K31/35 ,  A61K45/06 ,  A61K31/135 ,  A61K31/137 ,  A61K31/197 ,  A61K31/337 ,  A61K31/357 ,  A61K31/381 ,  A61K31/385 ,  A61K31/4015 ,  A61K31/44 ,  A61K31/454 ,  A61K31/485 ,  A61K31/505 ,  A61K31/517 ,  A61K31/55 ,  A61K31/465

摘要： This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

公开(公告)号：US20220259325A1

公开(公告)日：2022-08-18

申请号：US17498559

申请日：2021-10-11

申请人： Omeros Corporation ,  University of Leicester

发明人： Hans-Wilhelm Schwaeble ,  Gregory A. Demopulos ,  Thomas Dudler ,  Patrick Gray

IPC分类号： C07K16/40 ,  C07K16/18 ,  A61K39/395 ,  A61K45/06

摘要： In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.